Skip to main content
Clinical Trials/ISRCTN58328599
ISRCTN58328599
Completed
未知

Pancreatogastrostomy vs. pancreatojejunostomy for reconstruction of the pancreatic remnant after pancreatoduodenotomy: a prospective, randomised, controlled, metacentre study

Carlos III Institute of Health (Instituto de Salud Carlos III) (Spain)0 sites130 target enrollmentFebruary 7, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
Pancreatectomy
Sponsor
Carlos III Institute of Health (Instituto de Salud Carlos III) (Spain)
Enrollment
130
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 7, 2013
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Carlos III Institute of Health (Instituto de Salud Carlos III) (Spain)

Eligibility Criteria

Inclusion Criteria

  • 1\. Consecutive patients who will undergo pancreatodudodenectomy (DPC) at Hospital Clinico de Valencia and Hospital ?Dr Josep Trueta? in Girona Spain. Coordinated by ?Dr Josep Trueta? Hospital of Girona
  • 2\. Patients aged 18 to 80 years, either sex
  • 3\. Pancreatectomy is indicated because of a benign or malignant tumour of the pancreas, chronic pancreatitis or malignant neoplasm of other organs infiltrating the pancreas, provided the parenchyma of the pancreas is suitable for anastomosis

Exclusion Criteria

  • 1\. Patients who at the time of surgery are found not resectable
  • 2\. Associated resection of other organs, excluding the superior mesenteric vein
  • 3\. American Society of Anaesthesiologists (ASA) anesthetic risk 4 as the American Association of Anesthesiologists
  • 4\. Pancreatoduodenectomy (PD) for calcifying chronic pancreatitis
  • 5\. PD palliative leaving macroscopic tumor
  • 6\. Preoperative obstructive jaundice with bilirubin\> 300µmol or 15 mg/

Outcomes

Primary Outcomes

Not specified

Similar Trials